NASDAQ · Biotechnology

ICCC (ICCC) Stock

$10.75 -2.89% NASDAQ: ICCC Healthcare

Valuation

MetricValue
Price$10.75
Market Cap$97.25M
P/E Ratio-82.33
P/B Ratio3.31
P/S Ratio2.98
EPS (TTM)$-0.12
52-Week High$12.10
52-Week Low$4.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-3.70%
ROA-2.33%
ROCE7.14%
Gross Margin7.14%
Operating Margin7.14%
Net Margin-1.82%
Debt/Equity0.44
Current Ratio4.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$19.0M$19.0M$17.0M$26.0M$28.0M
Operating Profit$0$-2.0M$-6.0M$-2.0M$2.0M
Net Profit$0$-2.0M$-6.0M$-2.0M$-1.0M
EPS$-0.01$-0.32$-0.75$-0.26$-0.12
Op Margin1.3%-12.4%-32.9%-6.2%6.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$44.0M$45.0M$44.0M$45.0M$43.0M
Total Liabilities$12.0M$14.0M$19.0M$18.0M$15.0M
Cash$10.0M$6.0M$1.0M$4.0M$4.0M
Borrowings$10.0M$12.0M$17.0M$15.0M$13.0M

Latest News

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand Zacks · Jul 10, 2026 ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results GlobeNewswire · Jul 9, 2026 The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell Zacks · Jun 26, 2026 Top Stock Reports for JPMorgan, Novartis & Qualcomm Zacks · Jun 25, 2026 ICCC's Valuation Remains Premium: Is it Worth Overpaying for? Zacks · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$1.0M$-2.0M$-5.0M$0$2.0M
Investing Cash Flow$-4.0M$-8.0M$-4.0M$-1.0M$-2.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$3.0M$-4.0M$-5.0M$3.0M$0
Free Cash Flow$-2.0M$-6.0M$-7.0M$0$1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA19.68
FCF Yield3.78%
Quick Ratio2.60
Interest Coverage—
Return 1Y82.11%
Return 3Y123.97%
Return 5Y25.00%

Ownership

Insiders Held32.13%
Institutions Held21.62%
Institutions Float Held31.86%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC260,3272026-03-31
Morgan Stanley221,7162026-03-31
Renaissance Technologies, LLC151,7892026-03-31
Cresset Asset Management, LLC135,2672026-03-31
Bleichroeder LP101,5942026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About ICCC

ICCC is led by CEO F. Olivier Te Boekhorst, employs 69 people, headquartered in US, publicly traded since 1987.

ICCC stock trades at $10.75 with a market capitalization of $97.25M. The stock is valued at a price-to-earnings (P/E) ratio of -82.33, price-to-book of 3.31, price-to-sales of 2.98. Over the past 52 weeks the stock has ranged between $4.52 and $12.10, and currently trades 11.2% below its 52-week high.

On profitability, ICCC generates a return on equity (ROE) of -3.70%, return on capital employed of 7.14%, an operating margin of 7.14%, a net profit margin of -1.82%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides